Deborah Rathjen, PhD
CEO,
Carina Biotech
Australia
Dr Rathjen is an experienced and respected leader in the biotechnology and pharmaceutical industries within Australia and internationally, and has achieved in excess of $800 million in deals including partnerships with Merck & Co., J&J, Abbott (AbbVie), Nycomed (Takeda) and Merck KGaA. An immunologist by training, Dr Rathjen has extensive R&D experience in the areas of infection and immunity, inflammation, oncology and neuroscience, covering multiple treatment modalities. Dr Rathjen has led companies in Europe, US and Australia.
Sessions
-
26-Feb-2024Carina Biotech Limited
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}